RESPONSE SCIENTIFIC, INC.® (RSI) is a Research Biotechnology Corporation. RSI’s mission is to improve lives through innovative medical research and biomedical engineering leading to revolutionary new products and delivery systems for the general maintenance of health and the treatment and prevention of disease in humans and animals.
The Company has maintained a close working relationship with a team of the country’s leading biochemists and biomedical engineers for more than a decade. Currently, the Company is entering the commercialization stage for FDA-regulated and non-regulated healthcare products which represent a multibillion-dollar business.
The Company has recently trademarked the name Aegis Abuse Deterrence to describe the portion of its technology developed to improve the delivery and safety of drugs with a history of addiction potential and illicit manipulation. These include opioids, antidepressants, stimulants and OTC allergy/cold medications that contain pseudoephedrine.
RSI’s research pipeline includes the ongoing development of the world’s first orally delivered insulin and other protein derived medications. Utilizing the company’s microsphere delivery technology, the Company seeks to bring about the realization of what is considered by many the “Holy Grail” of the pharmaceutical industry. Laboratory testing to prove the ability to pass through the stomach acids and pancreatic enzymes, and enter the blood stream is scheduled to begin in 2018.